Alvotech (NASDAQ:ALVO) Stock Price Up 6.8% – Should You Buy?

Alvotech (NASDAQ:ALVO) shares were up 6.8% during mid-day trading on Thursday . The stock traded as high as $4.37 and last traded at $4.26. 796,346 shares were traded during mid-day trading, an increase of 25% from the average session volume of 638,732 shares. The stock had previously closed at $3.99.

More Alvotech News

Here are the key news stories impacting Alvotech this week:

• Positive Sentiment: Alvotech resubmitted U.S. biologics license applications for AVT05, a proposed Simponi/Simponi Aria biosimilar, and AVT06, a proposed Eylea biosimilar. Its partner, Dr. Reddy’s Laboratories, also resubmitted the AVT03 application for a Prolia/Xgeva biosimilar. FDA decisions are expected in the fourth quarter of 2026, creating significant regulatory catalysts. Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
• Positive Sentiment: The FDA closed its inspection of Alvotech’s Reykjavik manufacturing facility with a VAI classification, supporting management’s view that manufacturing and quality-system improvements are progressing. The company said production returned to planned levels late in the second quarter and that it is rebuilding supply to meet confirmed demand. Alvotech Business Update
• Positive Sentiment: Management reaffirmed a 2026 revenue outlook of $650 million to $700 million and adjusted EBITDA guidance of $180 million to $220 million. The revenue range’s midpoint is above the roughly $657.4 million analyst consensus, suggesting confidence in a stronger second half. Alvotech Reports Q2 Loss and Revenue Guidance
• Positive Sentiment: Alvotech raised approximately $165 million through an equity offering and private placement and added a $75 million term loan, improving funding for pipeline development and working capital.
• Neutral Sentiment: Second-quarter revenue of $105.77 million exceeded estimates of $103 million, but adjusted first-half revenue fell 30.8% year over year to $211.9 million as product and service revenue declined 48.3%. Alvotech Quarterly Results
• Negative Sentiment: Alvotech reported a quarterly loss of $0.11 per share, wider than the $0.05 expected loss and down from earnings of $0.14 per share a year earlier. Adjusted EBITDA also declined 12.7% to $46.9 million, while cash fell to $142.8 million from $172.4 million at the end of 2025. The new financing strengthens liquidity but increases dilution and debt obligations. Alvotech Q2 Earnings Report

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Evercore started coverage on shares of Alvotech in a research note on Friday, August 14th. They issued an “outperform” rating for the company. Weiss Ratings cut shares of Alvotech from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 9th. Finally, Wall Street Zen downgraded shares of Alvotech from a “hold” rating to a “sell” rating in a research report on Saturday, May 23rd. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Alvotech currently has a consensus rating of “Hold” and a consensus target price of $7.60.

Alvotech Price Performance

The company has a 50-day simple moving average of $3.66 and a 200-day simple moving average of $3.75. The stock has a market cap of $1.26 billion, a PE ratio of -16.72 and a beta of 0.18.

Alvotech (NASDAQ:ALVO) last issued its earnings results on Thursday, August 20th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.06). Alvotech had a negative return on equity of 11.92% and a negative net margin of 14.36%.The company had revenue of $105.77 million for the quarter, compared to analysts’ expectations of $103.00 million. On average, equities analysts expect that Alvotech will post 0.05 EPS for the current fiscal year.

Institutional Trading of Alvotech

Institutional investors have recently added to or reduced their stakes in the stock. ProShare Advisors LLC grew its position in Alvotech by 24.0% during the fourth quarter. ProShare Advisors LLC now owns 13,826 shares of the company’s stock worth $71,000 after buying an additional 2,675 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Alvotech by 25.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,211 shares of the company’s stock worth $78,000 after acquiring an additional 3,110 shares in the last quarter. Magnetar Financial LLC purchased a new stake in shares of Alvotech during the 3rd quarter worth approximately $86,000. Orion Porfolio Solutions LLC acquired a new stake in shares of Alvotech in the 3rd quarter worth approximately $92,000. Finally, Stifel Financial Corp acquired a new stake in shares of Alvotech in the 4th quarter worth approximately $108,000.

Alvotech Company Profile

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high?quality, cost?effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in?house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).